MTRC released report on funding decisions by payers for medical technologies in Europe

28

May 2019

The funding reflects a willingness to pay for procedure or device by payers. Funding is different from reimbursement, which is the method to pay for the procedure (e.g. via diagnosis-related group). 

The procedure can have a procedure code and be grouped into DRG with sufficient tariff, but payers do not want to pay for the procedure, which results in this procedure not having coverage in the target country. This is the case, for example, for robotic surgery in England. Robotic surgery is approved for funding by NHS England for some indications (e.g. prostatectomy) and not approved for others (e.g. bladder cancer).

Therefore, the funding represents the unique market access challenge, which should be well understood. Explicit funding frameworks exist in England, Germany, the Netherlands, Norway, and Switzerland.

MTRC released a report on funding decisions by payers for medical technologies in Europe: 

  • England: All commissioning policies by NHS England for nationally commissioned procedures; procedures from the List of restricted technologies from one Clinical Commissioning Group - North Staffordshire CCG. Service specifications are not included
  • Germany: Technologies included into G-BA Directives for hospital care
  • Netherlands: Decisions about coverage of procedures in the Basic Health Insurance by the Dutch Health Care Institute (Zorginstituut Nederland)
  • Norway: Decisions of the Decision Forum of the "New Methods" framework
  • Switzerland: Decisions about coverage of services within statutory health insurance by the Federal Office of Public Health

Key features of the report:

  • Devices, procedures and IVD tests - Data about all non-drug decisions are included into the report
  • Overview of funding frameworks - Brief overview of each funding framework is provided
  • Key information and summary statistics - For each report, information about type of technology (e.g. neurostimulator, cardiovascular) and decisions (positive or negative) is included. Summary statistics is provided
  • List of all published decisions (>1000) - All decisions per country/organization are listed in the table format including organization, title, type of technology, decision and web-link. Optionally, access the full list in MS Excel

You can download sample pages and order the report here

The latest related news

25

Mar 2022

On March 4, 2022, the Dutch Healthcare Institute (Zorginstituut Nederland, ZIN) announced three projects which received a subsidy under the "Subsidy scheme for promising care" in 2022 for research of a new minimally invasive endoscopy-guided surgery in patients with spontaneous cerebral hemorrhage, oral immunotherapy in children to cure a food allergy and cutting the diaphragm band in chronic abdominal complaints.

Read more

23

Mar 2022

In late January 2022, Swedish Medical Technologies Product (MTP) Council issued an updated version of recommendations regarding gene expression analysis for decision-making on the adjuvant breast cancer treatment, initially published in November 2021. The recommendation to the regions remains the same. The changes were only concerned with the clarification of some facts.

Read more

22

Mar 2022

On February 17, 2022, the Federal Joint Committee (G-BA) has decided to include the method of matrix-associated autologous chondrocyte implantation (M-ACI) on the knee joint in the case of symptomatic cartilage damage in the lists of reimbursed procedures in the hospital and ambulatory settings.

Read more

16

Mar 2022

In February 2022, Swedish Medical Technologies Product (MTP) Council issued an updated recommendation on FreeStyle Libre for continuous glucose monitoring in type 2 diabetes (T2D). The initial recommendations were published by NT Council in 2018 and updated by MTP Council in 2020 to include FreeStyle Libre 2. In the 2022 update, MTP Council decreased the Hba1c limit from 70 to 60 mmol/mol and added a statement on lifestyle changes and treatment optimization with non-insulin antidiabetic drugs.

Read more

11

Mar 2022

On February 07, 2022, the Dental and Pharmaceutical Benefits Agency has announced the withdrawal of the assessments of the PhysioMem PM 100 and CardioMem CM 100 XT and the finalization of the assessments of the Zenicor ECG, Coala Heart Monitor Pro, and KardiaMobile. For the conducted assessments, it was outlined that the portable devices provide more limited information than standard ECG measurements; therefore, it was mainly estimated for atrial fibrillation.

Read more